ニュース
Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by the accumulation of scar tissue in the ...
Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.
The White House has blamed the Biden administration for failing to advance domestic production or fill the reserve.
Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...
Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...
Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being ...
Amphastar has signed an exclusive license agreement with Anji for the development, production, use and commercialisation of 3 ...
PharmaTher's ketamine product is the first to be approved in an analgesic setting by the FDA, offering competition to opiates ...
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...
Insmed’s drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...
AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する